摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(2,6-dimethyl-phenyl)-piperidine hydrochloride | 371981-26-9

中文名称
——
中文别名
——
英文名称
4-(2,6-dimethyl-phenyl)-piperidine hydrochloride
英文别名
4-(2,6-dimethylphenyl)piperidine;hydrochloride
4-(2,6-dimethyl-phenyl)-piperidine hydrochloride化学式
CAS
371981-26-9
化学式
C13H19N*ClH
mdl
——
分子量
225.762
InChiKey
JYQUXGDHCUBSLA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.19
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    12
  • 氢给体数:
    2
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    1H-吲哚-2-甲醛4-(2,6-dimethyl-phenyl)-piperidine hydrochloride 在 cyanoborohydride on polymer support 、 溶剂黄146 作用下, 以 四氢呋喃甲醇 为溶剂, 反应 15.0h, 生成 2-[4-(2,6-dimethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole
    参考文献:
    名称:
    [EN] SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR
    [FR] LIGANDS D'INDOLE SUBSTITUES DESTINES UN RECEPTEUR ORL-1
    摘要:
    描述了用于调节ORL-1受体活性的新配体,适用于需要此类受体的患者,并用于预防和治疗依赖于该受体刺激的疾病。这些新化合物符合结构式(I),其中Q是式(II)的一个部分,而R、R0、R1、R2、R3、R4、R5、R6在描述中进一步定义。
    公开号:
    WO2005005411A1
点击查看最新优质反应信息

文献信息

  • [EN] BENZOSUBERONYLPIPERIDINE COMPOUNDS AS ANALGESICS<br/>[FR] COMPOSES DE BENZOSUBERONYLPIPERIDINE COMME ANALGESIQUES
    申请人:SMITHKLINE BEECHAM SPA
    公开号:WO2001083454A1
    公开(公告)日:2001-11-08
    Compounds of formula (I) or a derivative thereof, wherein; R is C1-6alkyl, C3-7cycloalkyl, C1-6alkoxy, hydroxy, halo, C1-6alkenyl, C1-6alkynyl, amino, C1-6alkylamino, di(C1-6alkyl)amino, hydroxyC1-6alkyl, C1-6alkoxyC1-6alkyl, aminoC1-6alkyl, (C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)aminoC1-6alkyl; R1 is hydrogen or R; R2 is hydroxy, C¿1-6?alkoxy, amino, C1-6alkylamino, di(C1-6alkyl)amino; R?3¿ is hydrogen or C¿1-6?alkyl; R?4 and R5¿ are each independently selected from the list consisting of perhaloC¿1-6?alkyl, hydrogen, halo, C1-6alkyl, C1-6alkoxy, hydroxy, amino, C1-6alkylamino, di(C1-6alkyl)amino, hydroxyC1-6alkyl, C1-6alkoxyC1-6alkyl, aminoC1-6alkyl, (C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)aminoC1-6alkyl, aryl, and COX wherein X may be hydroxy, C1-6alkoxy, C1-6alkyl, amino, C1-6alkylamino, or di(C1-6alkyl)amino; with the proviso that, when R?3¿ is hydrogen, then R?4 and R5¿ are not both hydrogen; and wherein any alkyl group or the alkyl moiety of any group containing such a moiety may be substituted one or more times by halo; are ligands of the ORL-1 receptor and are useful in therapy.
    式(I)或其衍生物的化合物,其中:R为C1-6烷基,C3-7环烷基,C1-6烷氧基,羟基,卤素,C1-6烯基,C1-6炔基,氨基,C1-6烷基氨基,二(C1-6烷基)氨基,羟基C1-6烷基,C1-6烷氧基C1-6烷基,氨基C1-6烷基,(C1-6烷基)氨基C1-6烷基,二(C1-6烷基)氨基C1-6烷基;R1为氢或R;R2为羟基,C1-6烷氧基,氨基,C1-6烷基氨基,二(C1-6烷基)氨基;R3为氢或C1-6烷基;R4和R5各自独立地从以下列表中选择:全卤素C1-6烷基,氢,卤素,C1-6烷基,C1-6烷氧基,羟基,氨基,C1-6烷基氨基,二(C1-6烷基)氨基,羟基C1-6烷基,C1-6烷氧基C1-6烷基,氨基C1-6烷基,(C1-6烷基)氨基C1-6烷基,二(C1-6烷基)氨基C1-6烷基,芳基和COX,其中X可以是羟基,C1-6烷氧基,C1-6烷基,氨基,C1-6烷基氨基或二(C1-6烷基)氨基;但是,当R3为氢时,R4和R5不同时为氢;其中任何烷基或含有此类基团的任何基团的烷基部分均可被卤素取代一次或多次;是ORL-1受体的配体,并且在治疗中有用。
  • Benzosuberonylpiperdine compounds as analgesics
    申请人:——
    公开号:US20040029917A1
    公开(公告)日:2004-02-12
    Compounds of formula (I) or a derivative thereof, wherein; R is C 1-6 allkyl, C 3-7 cycloalkyl, C 1-6 alkoxy, hydroxy, halo, C 1-6 alkenyl, C 1-6 allkynyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, hydroxyC 1-6 alkyl, C 1-6 akoxyC 1-6 alkyl, aminoC 1-6 allkyl, (C 1-6 allkyl)aminoC 1-6 alkyl, di(C 1-6 allkyl)aminoC 1-6 alkyl; R 1 is hydrogen or R; R 2 is hydroxy, C 1-6 alkoxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino; R 3 is hydrogen or C 1-6 alkyl; R 4 and R 5 are each independently selected from the list consisting of perhaloC 1-6 alkyl, hydrogen, halo, C 1-6 alkyl, C 1-6 alkoxy, hydroxy, amino, C 1-6 akylamino, di(C 1-4 alkyl)amino, hydroxyC 1-6 alkyl, C 1-6 akoxyC 1-6 alkyl, aminoC 1-6 allkyl, (C 1-4 alkyl)aminoC 1-6 alkyl, di(C 1-4 alkyl)aminoC 1-4 alkyl, aryl, and COX wherein X may be hydroxy, C 1-6 alkoxy, C 1-6 alkyl, amino, C 1-6 alkylamino, or di(C 1-6 allkyl)amino; with the proviso that, when R 3 is hydrogen, then R R 4 and R 5 are not both hydrogen; and wherein any alkyl group or the alkyl moiety of any group containing such a moiety may be substituted one or more times by halo; are ligands of the ORL-1 receptor and are useful in therapy. 1
    式(I)或其衍生物的化合物,其中:R是C1-6烷基,C3-7环烷基,C1-6烷氧基,羟基,卤素,C1-6烯基,C1-6炔基,氨基,C1-6烷基氨基,二(C1-6烷基)氨基,羟基C1-6烷基,C1-6烷氧基C1-6烷基,氨基C1-6烷基,(C1-6烷基)氨基C1-6烷基,二(C1-6烷基)氨基C1-6烷基;R1是氢或R;R2是羟基,C1-6烷氧基,氨基,C1-6烷基氨基,二(C1-6烷基)氨基;R3是氢或C1-6烷基;R4和R5各自独立地选自以下列表中的物种:全卤素C1-6烷基,氢,卤素,C1-6烷基,C1-6烷氧基,羟基,氨基,C1-6烷基氨基,二(C1-4烷基)氨基,羟基C1-6烷基,C1-6烷氧基C1-6烷基,氨基C1-6烷基,(C1-4烷基)氨基C1-6烷基,二(C1-4烷基)氨基C1-4烷基,芳基,和COX,其中X可以是羟基,C1-6烷氧基,C1-6烷基,氨基,C1-6烷基氨基或二(C1-6烷基)氨基;但是,当R3是氢时,R、R4和R5不能同时为氢;其中任何烷基或含有此类基团的任何基团的烷基部分可以被卤素取代一次或多次;是ORL-1受体的配体,并且在治疗中有用。
  • Substituted indole ligands for the ORL-1 receptor
    申请人:Ronzoni Silvano
    公开号:US20090275555A1
    公开(公告)日:2009-11-05
    New ligands for the ORL-1 receptor are described, useful for antagonising the activity of said receptors in a patient in need thereof, and for preventing and treating illnesses dependent on the activation of this receptor. The new compounds conform to structural formula (I) wherein R1, R2, R3, R4 are further defined in the description.
    本文描述了ORL-1受体的新配体,可用于拮抗需要该受体活性的患者,并用于预防和治疗依赖于该受体激活的疾病。新化合物符合结构式(I),其中R1,R2,R3,R4在描述中进一步定义。
  • Substituted indole ligands for the orl-1 receptor
    申请人:Consonni Alessandra
    公开号:US20070197603A1
    公开(公告)日:2007-08-23
    New ligands for the ORL-1 receptor are described, useful for modulating the activity of said receptors in a patient in need thereof, and for preventing and treating illnesses dependent on the stimulation of this receptor. The new compounds conform to structural formula (I), wherein Q is a moiety of formula: and R, R 0 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 are further defined in the description.
    本文描述了ORL-1受体的新配体,可用于调节患者中该受体的活性,并用于预防和治疗依赖于该受体刺激的疾病。新化合物符合结构式(I),其中Q是以下式子的一个基团:而R,R0,R1,R2,R3,R4,R5,R6在描述中进一步定义。
  • BENZOSUBERONYLPIPERIDINE COMPOUNDS AS ANALGESICS
    申请人:GlaxoSmithKline S.p.A.
    公开号:EP1278729A1
    公开(公告)日:2003-01-29
查看更多